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Abstract Deletion of chromosome 9p21 is a crucial
event for the development of several cancers including
acute lymphoblastic leukemia (ALL). Double strand
breaks (DSBs) triggering 9p21 deletions in ALL have
been reported to occur at a few deWned sites by illegiti-
mate action of the V(D)J recombination activating protein
complex. We have cloned 23 breakpoint junctions for a
total of 46 breakpoints in 17 childhood ALL (9 B- and 8
T-lineages) showing diVerent size deletions at one or both
homologous chromosomes 9 to investigate which particular
sequences make the region susceptible to interstitial deletion.
We found that half of 9p21 deletion breakpoints were
mediated by ectopic V(D)J recombination mechanisms
whereas the remaining half were associated to repeated
sequences, including some with potential for non-B DNA
structure formation. Other mechanisms, such as microho-
mology-mediated repair, that are common in other can-
cers, play only a very minor role in ALL. Nucleotide
insertions at breakpoint junctions and microinversions
Xanking the breakpoints have been detected at 20/23 and
2/23 breakpoint junctions, respectively, both in the
presence of recombination signal sequence (RSS)-like
sequences and of other unspeciWc sequences. The
majority of breakpoints were unique except for two cases,
both T-ALL, showing identical deletions. Four of the 46
breakpoints coincide with those reported in other cases,
thus conWrming the presence of recurrent deletion hot-
spots. Among the six cases with heterozygous 9p dele-
tions, we found that the remaining CDKN2A and
CDKN2B alleles were hypermethylated at CpG islands.
Introduction
Unraveling the cause of genomic structural rearrangements
has become a hot topic in human genetics. The comprehen-
sion of the nucleotide sequences leading to genomic insta-
bility might ultimately lead to understand whether
deleterious imbalances, both constitutional and acquired,
occur at random in people sharing apparently identical
genome sequences at a certain locus or are linked to spe-
ciWc haplotypes. In the last years three major mechanisms
had been proposed, i.e., non-allelic homologous recombi-
nation (NAHR), responsible for recurrent rearrangements,
non-homologous end joining (NHEJ), and Fork Stalling
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and Template Switching (FoSTeS), the latter two associ-
ated with non-recurrent rearrangements (Gu et al. 2008).
Most of these mechanisms had been extrapolated by study-
ing patients with constitutional imbalances. Very few stud-
ies have focused on the molecular mechanisms leading to
acquired rearrangements although their importance in
tumor’s initiation and progression is obvious as recently
demonstrated by the Wnding that the acquired JAK2V617F
mutation, in myeloproliferative neoplasms, is associated
with a germline haplotype block that includes the 3 portion
of JAK2 (Jones et al. 2009; Olcaydu et al. 2009; Kilpivaara
et al. 2009). This Wnding indeed implies the existence of a
strong, but uncharacterized, interaction between somatic
and germline genetics (Campbell 2009). We cloned 23
breakpoint junctions, for a total of 46 breakpoints, in 17
ALL of childhood (9 B- and 8 T-lineages; 2–4 breakpoints
per case according to the presence of diVerent heterozy-
gous/homozygous deletions) showing non-recurrent dele-
tions at one or both homologous chromosomes 9; all
deletions contained CDKN2A, most also involved
CDKN2B. These 9p21.3 genes encode three cell cycle
inhibitory proteins: p15INK4b, p16INK4a, and p14ARF (Gil and
Peters 2006). Homozygous deletions removing p16 or het-
erozygous deletions with inactivation of the normal allele
occur in a variety of cancers (Drexler 1998; Ruas and
Peters 1998; Orlow et al. 1999; Bertin et al. 2003; Irving
et al. 2005; Murao et al. 2006; Kohno and Yokota 2006;
StreVord et al. 2007; Usvasalo et al. 2008; Bungaro et al.
2009). Therefore, this locus is considered a paradigm of the
two-hit hypothesis (Knudson 1971). In the last years, both
lymphoid leukemias and other types of tumors have been
analyzed for the 9p21 deletion (Kitagawa et al. 2002; Florl
and Schulz 2003; Sasaki et al. 2003; Kohno and Yokota
2006). Kohno and Yokota (2006) mapped the breakpoints
of 21 lymphoid leukemia cases, 21 lung cancer cases, and
32 other solid cancer cases at a 10-kb resolution. They
found that regions of breakpoint clustering were diVerent in
diVerent malignancies and that the majority of the 20
cloned breakpoints in lymphoid leukemia clustered at a
few breakpoint sites, each <15-bp in size. The sites were
Xanked by sequences similar to the heptamer-RSSs which
are targeted by the RAG complex in V(D)J recombination,
as previously shown also by Cayuela et al. (1997).
While screening by genome-wide array-CGH a bone
marrow sample of 65 childhood B- and T-ALLs, we
detected 18 cases (27.7%) having either heterozygous or
homozygous 9p21 deletions. We then performed a detailed
analysis of breakpoint junctions in only 17 of them (9 B-
and 8 T-ALLs) in order to better understand which particu-
lar sequences make the 9p21 region susceptible to
interstitial deletions. Moreover, we have studied, by CpG
island methylation analysis, the activation/inactivation state
of CDKN2A and CDKN2B in heterozygous deletions.
Materials and methods
Patients
Sixty-Wve pediatric patients, aged between 4 months and
18 years (median age 5 years and 3 months), were included
in the Wrst screening through whole-genome array-CGH at
a 100-kb resolution (Kit 44B, Agilent Technologies, Santa
Clara, CA). Of the 65 children, 53 were aVected by B-ALL,
whereas 12 had T-lineage ALL (see Supplementary Table 1
for patients characteristics). All patients were diagnosed
and treated in a single center (Oncoematologia Pediatrica
Fondazione IRCCS Pavia, Italy) according to the front-line
protocol of the Italian Association of Pediatric Hematology
and Oncology (AIEOP) for childhood ALL (AIEOP LLA
2000) or the relapse protocol (AIEOP LLA REC 2003),
with the only exception of a 4-month-old child who
received chemotherapy according to the Interfant 99 proto-
col (Pieters et al. 2007). The study received approval by the
local Institutional Review Board, and informed consent was
obtained from all patients’ parents. Patients were censored
as of 1 August 2007, the median follow-up time being
3.3 years (range 3–78 months).
The diagnosis of ALL was based on morphological,
cytochemical, and immunophenotypical criteria. Eligible
patients had fewer than 3% blasts positive for myeloperoxi-
dase or Sudan black, and were negative for non-speciWc
esterase according to the French–American–British criteria.
Positivity criteria for immunophenotyping were deWned
according to the BFM-family criteria, with the limits of
20% for surface antigens and 10% for intracellular markers
(van der Does-van den Berg et al. 1992). The presence of
the translocations t(9;22) and t(4;11) was systematically
screened by reverse transcriptase-polymerase chain reac-
tion (RT-PCR) in a centralized laboratory (van Dongen
et al.  1999). CR was deWned as the absence of physical
signs of leukemia or detectable leukemia cells on blood
smears, a BM with active haematopoiesis and fewer than
5% leukemia blast cells and normal cerebrospinal Xuid.
Patients with 9p21 deletions were selected from the Wrst
screening: ten were aVected by B-ALL and 8 with T-ALL.
Customized array-CGH
Each childhood ALL sample was analyzed with a 44B
Agilent platform for genomic array having in average an
oligomer every 35-kb. Because the minimum positive call
was considered three consecutive oligomers with a log2
ratio diVerent from zero [cut-oV log2 ratios: ¡1 and ¡4
for constitutional heterozygous and homozygous dele-
tions, respectively; +0.5 for constitutional duplications;
+1 for constitutional triplication; a log2 ratio of ¡0.3 is
representative of a cellular mosaic of about 50%, asHum Genet (2009) 126:511–520 513
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demonstrated by dilution experiments (data not shown)],
the true resolution of the platform was about 100-kb. As
reference DNA we used a pool of female or male lympho-
cytes (Promega, Milan, Italy). All CNVs not reported in
the database of genomic variants (http://projects.tcag.ca/
variation/) and not already known to be associated with
leukemia were conWrmed as de novo or acquired with a
new array experiment using patient’s saliva as reference
DNA. Each case with 9p21 deletion was reanalyzed on a
customized platform generated using the eArray software
(http://earray.chem.agilent.com/); the probes (60-mer oli-
gonucleotides) were selected from those available in the
Agilent database and are speciWc for the 9p21 region. The
array was made of 44.000 probes (custom 44K, Agilent
Technologies) of which 19.000 represented the region
under study (from 19 to 25 Mb), allowing molecular pro-
Wling of 9p21 aberrations with a resolution of »1 and
»10-kb in single copy and repeated regions, respectively.
DNA of every ALL sample was extracted from bone mar-
row (BM) mononuclear cells with at least 80% of blasts
(range 80–100%, median value 90%, evaluated morpho-
logically and through Xow cytometry), after gradient sep-
aration, or peripheral blood (PB, only when the presence
of leukemia blasts in the periphery was equal to or supe-
rior than 80%) using a QIAamp DNA Blood Mini Kit
(Qiagen, Milan, Italy) according to the manufacturer’s
protocol. Test DNA (from leukemia BM or PB leukemia
cells, 500 ng) and control DNA (Human Genomic DNA
Female or Male, Promega, Madison, WI, 500 ng) were
double-digested with RsaI and AluI (Promega) for 1 h at
37°C. After digestion, samples were incubated at 65°C for
20 min to inactivate the enzymes then labeled by random
priming (Agilent Technologies) for 2 h using cyanine5-
dUTP for the test DNA and cyanine3-dUTP (Agilent
Technologies) for the control DNA. Labeled DNAs were
incubated at 65°C for 10 min and then cleaned with
Microcon YM-30 Wlter units (Millipore, Billerica, MA).
PuriWed samples were brought to a total volume of 21 l
in 1£TE (pH 8.0, Promega), and yield and speciWc activity
were determined for each sample using a NanoDrop
ND-1000 UV–VIS Spectrophotometer (Agilent Technol-
ogies). The appropriate cyanine 5- and cyanine 3-labeled
samples were combined in a total volume of 39 l. After
sample denaturation and pre-annealing with 5 l of
Human Cot-1 DNA (Invitrogen, Carlsbad, CA), hybridization
was performed at 65°C with shaking for 24 h. After two
washing steps, the array was analyzed on the Agilent
scanner (DNA Microarray Scanner with Sure Scan High-
Resolution Technology, Model G2565CA, Agilent Tech-
nologies) and then by the Feature Extraction software
(v9.1). Graphical overview was obtained using the CGH
analytics software (v3.4.27). The positions of oligomers
refer to the Human Genome March 2006 assembly (hg18).
Results were also visualized using the UCSC Genome
Browser website (http://genome.ucsc.edu/).
Breakpoint mapping
Breakpoints were cloned by long range PCR using primers
that recognize sequences Xanking the distal and proximal
breakpoints, respectively, based on the customized array-
CGH data. All primer sequences are available on request.
Long-range PCRs were performed with JumpStart Red
ACCUTaq LA DNA polymerase (Sigma-Aldrich, Stein-
heim, Germany) and the following protocol: 30 s at 96°C,
35 cycles of 15 s at 94°C/20 s at 58°C/10 min at 68°C,
5m i n   Wnal elongation time. Sequencing reactions were per-
formed with a BigDye Terminator Cycle Sequencing kit
(Applied Biosystems, Foster City, CA) and run on an ABI
Prism 3130xl Genetic Analyzer.
DNA methylation assay
Sodium bisulWte conversion of unmethylated cytosine resi-
dues to uracil in DNA samples (700 ng) was performed
using a DNA Methylamp™-One step-DNA modiWcation
kit (Epigentek, Brooklyn, NY) according to the manufac-
turer’s protocol. Primers for CDKN2A and CDKN2B were
designed with CpG Ware software (http://apps.serologi-
cals.com/cpgware/dna_form2.html) to speciWcally amplify
each of the sequences, based upon chemically induced
diVerences. Methylation-speciWc polymerase chain reaction
(MS-PCR) ampliWcation was carried out using primers spe-
ciWc for either wild-type, methylated or unmethylated DNA
(see Supplementary Table 4 for details). The PCR mixture
contained 10£ Taq reaction buVer (200 mM Tris pH 8.4,
500 mM KCl), 50 mM MgCl2 ( Wnal concentration
1.5 mM), 10 mM dNTPs mixture (Wnal concentration
0.2 mM each), 20 mM primers (300 ng each per reaction),
1.5 units of Taq DNA polymerase (all material from Invit-
rogen, Carlsbad, CA) and bisulWte-modiWed (»100 ng) or
unmodiWed DNA (»100 ng) for a Wnal volume of 30 l.
PCR speciWc for unmodiWed DNA also included 0.5 M
betain (Sigma-Aldrich, Steinheim, Germany). AmpliWca-
tion was carried out in a thermocycler, with the following
PCR cycling proWle: preheating at 96°C for 5 min, followed
by 95°C for 30 s, annealing temperature for 30 s (see Sup-
plemenray Table 4 for each annealing temperature), 72°C
for 30 s for 35 cycles, and a Wnal extension at 72°C for
7 min. The PCR samples were loaded onto a 2.5% agarose
gel, stained with ethidium bromide, and directly visualized
under ultraviolet (UV) illumination. MS-PCR was also per-
formed on Wve positive controls whit 9p21 deletions,
detected by whole-genome array-CGH, from other diVerent
type of cancers and on the same number of negative
controls.514 Hum Genet (2009) 126:511–520
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To conWrm the methylation state of CDKN2A and
CDKN2B, an aliquot of each PCR product was cut with
BstUI (New England Biolabs, Beverly, MA), which recog-
nizes the sites of methylation (5…CGCG…3 and
3…GCGC…5), for 1 h at 60°C, then loaded on a 2.5%
agarose 1£TAE gel. Cleavage occurs if the CGCG
sequence has been retained during bisulWte conversion due
to the methylated status of the cytosine residues. A second
aliquot of the PCR products was puriWed with UltraClean
PCR Clean-up (MoBio. Labs, Carlsbad, CA) according to
the manufacturer’s protocol and sequencing reactions were
performed by automated DNA Sequencing (PE Applied
Biosystem).
Results
Genome-wide array-CGH analysis detected several copy
number aberrations in 90.7% (59/65) of the cases (Supple-
mentary Table 2). The most frequent imbalances involved
6q16.2-q21 (5 cases), 12p13.1-p13.2 (13 cases, of which 9
encompassing CDKN1B), and 14q32.33 encompassing the
IgH locus (30 cases). All these imbalances are beyond the
aims of this study but they are summarized in Supplemen-
tary Table 2. The frequency of homozygous/heterozygous
9p21 deletions was 27.7% (18/65) and was higher in
T-ALLs than in B cell precursor ALLs [66.7% (8/12) vs.
18.9% (10/53)]. In most samples, the log2 ratio was
between ¡0.3 and ¡0.8 for heterozygous and between ¡2
and ¡3.5 for homozygous deletions, due to normal cells
contamination. Customized array-CGH experiments con-
Wrmed the data obtained on the 44K platform and allowed
us to better characterize the size of each deletion (Fig. 1;
Supplementary Table 3). The region between the last nor-
mal and the Wrst deleted oligomeres ranged between 51 bp
and 7.8 Kb. Deletion size and location were diVerent in all
cases, except for two cases characterized by a deletion
with proximal and distal identical breakpoints (888-06 and
314-07, Supplementary Table 3). Cloning of the break-
point junctions allowed us to characterize the precise size
of each deletion (Fig. 2a) and to identify the sequences
Xanking each breakpoint junction (Table 1). All dele-
tions always spanned at least CDKN2A and either
CDKN2B or MTAP (Fig. 2b). In one case (1329-07), the
shorter CDKN2A isoforms were not deleted. When hetero-
zygous deletions of CDKN2A, or both CDKN2A and
CDKN2B, were present (6 cases: 888-06, 46-07, 1623-06,
1329-07, 886-07 and 547-07; Fig. 2a; Supplementary
Table 3), the remaining allele was always methylated at its
promoter CpG island (Fig. 3). Twenty-three 9p21 break-
point junctions (for a total of 46 breakpoints) were cloned
from only 17 childhood acute lymphoblastic leukemia
cases, 8 T- and 9 B-ALLs (Table 1), because the cloning
failed for one B-ALL (case 884-07). Junctions were cloned
from 11 cases with two breakpoints (either heterozygous
deletions or identical homozygous deletions), 4 cases with
four breakpoints (heterozygous/homozygous deletions
with diVerent breakpoints) and 2 cases (888-06 and 314-
07) with multiple deletions on the same allele for a total of
four breakpoints per case. One B-ALL case (402-06), ana-
lyzed both at onset and relapse, presented identical 9p21
deletion breakpoints. Only one T-ALL case (1460-07,
BP1) showed a breakpoint junction with an overlap of six
nucleotides, evidence of microhomology-related rear-
rangement. Two junctions, one from a T-ALL case (1562-
06) and one from a B-ALL case (1327-07) had neither
insertions nor nucleotide overlaps. A de novo insertion
1–12 nucleotides in size (average 4.8 nucleotides, T cells
4.4 nucleotides, B cells 5.3 nucleotides) was present at all
other breakpoint junctions. One T cell leukemia (219-07,
BP1) had at its proximal breakpoint a 227 bp inversion
preceded by three extra nucleotides not present in the con-
sensus sequence. The second allele from the same subject
(219-07, BP2) contained a 427 bp insertion from chromo-
some 4q32.2. A B-ALL case (1623-06) carried at its distal
breakpoint a 253 bp inversion bracketed by 15 bp of dupli-
cated inverted sequence and followed by seven extra
nucleotides not present in the genomic consensus
sequence. Two T-ALL cases (547-07 and 217-07) had
essentially the same junctions, with distal breakpoints one
base apart in an Alu repeat and proximal breakpoints in the
same (TG)n repeat; both cases had de novo insertions:
AGG in one, TTTAAGTAAG in the other. A third B-ALL
case (46-07) had its proximal breakpoint in the same
(TG)n repeat. Two cases (888-06 and 314-07) carried two
deletions on the same chromosome, one spanning
CDKN2A, the other more proximal (BP2: 22486528 to
22494344). Sequence analysis of the second deletion
showed that both cases had the same breakpoints. Dele-
tion-speciWc PCR ampliWcation of 21 healthy controls (not
shown) demonstrated that the deletion was present in 12 of
them and should, therefore, be considered a genomic
polymorphism. Copy number variations in the same interval
are listed in the Database of Genomic Variants (http://
projects.tcag.ca/variation/) (Iafrate et al. 2004) as Varia-
tion_37473 (Cooper et al. 2008) and Variation_7739 (de
Smith et al. 2007).
All repeated sequences located within 60 bp from the
breakpoints are listed in Table 1. Twenty-seven of the 46
breakpoints (58.7%) are actually inside a repeat. The
more frequent family of repeats was LINE (12 break-
points; T: 3; B: 9); SINE (5 breakpoints; T: 3; B: 2),
simple repeats (4 breakpoints; T: 3; B: 1), DNA (3
breakpoints; T: 2; B: 1) and LTR (3 breakpoints; T: 2; B:
1) were also represented. In 11 junctions, repeats were
present at both breakpoints; in nine junctions, atHum Genet (2009) 126:511–520 515
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one breakpoint; in three junctions, no repeats were
involved.
To assess the involvement of illegitimate V(D)J recom-
bination in 9p21 deletions, RSS-like sequences were exam-
ined. The 23 bp sequence Xanking each breakpoint was
visually searched for 5-CAC trinucleotides in the forward
direction and the 3-GTG trinucleotides in the reverse
direction. This choice was due to the fact that the CAC
trinucleotide in the heptamer-RSS (CACAGTG) is the only
part of the RSSs indispensable for V(D)J recombination
(Hesse et al. 1989; Akamatsu et al. 1994) and nucleotide
loss as a result of V(D)J recombination does not extend
over 20 bp (Nobori et al. 1996). Sequences similar to the
nonamer RSS (ACAAAAACC) were also considered. RSSs
sequences were found at 12/24 breakpoints in our T-ALL
cases and in 12/22 breakpoints in B-ALLs (Table 1).
Discussion
In the past few years, several studies have focused on
understanding the origin of deletions and duplications lead-
ing to both benign and pathogenic copy number variations
(CNVs). Some constitutional CNVs are obviously of
meiotic origin (Turner et al. 2008; Gu et al. 2008). For what
concerns acquired CNVs, it seems now very clear that they
are not limited to tumor processes. The concept of a stable
somatic genome has been challenged by the Wnding of
extensive genomic copy number variation in mouse embryonic
stem cells suggesting a similar situation in humans (Liang
et al. 2008). These data reinforced previous studies show-
ing that mitotic ectopic exchanges occurring in the soma
and germ line mainly contribute to de novo occurrence of
human alpha-globin genes duplications, whereas meiotic
exchanges between homologous chromosomes generate a
minority of sperm duplications (Lam and JeVreys 2007).
Somatic CNVs occurrence has also been demonstrated by
the Wnding that identical twins can diVer in CNV (Bruder
et al. 2008). Deletions at 9p21 deserve attention because
removal of the p16 tumor suppressor gene is a genetic alter-
ation frequently observed in a variety of human cancers
(Drexler 1998; Ruas and Peters 1998; Orlow et al. 1999;
Bertin et al. 2003; Irving et al. 2005; Murao et al. 2006;
Kohno and Yokota 2006; StreVord et al. 2007; Usvasalo
et al. 2008; Bungaro et al. 2009). Kohno and Yokota (2006)
reported that DNA double strand breaks (DSBs) triggering
Fig. 1 An example of custom array-CGH results: case 217-07. a Chro-
mosome 9 proWle with 9p21 deletion indicated by the box, b enlargement
of the 9p21 region showing a homozygous deletion, c further enlargement
of the locus under study; the arrows point to the edge between normal and
deleted oligomeres516 Hum Genet (2009) 126:511–520
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9p21 deletions in lymphoblastic leukemia lines are formed
at a few deWned sites by the illegitimate action of the
recombination-activating genes (RAG) protein complex in
V(D)J recombination, as previously reported (Cayuela
et al.  1997), while 9p21 DSBs in solid tumor lines are
formed at unspeciWc sites by microhomology-mediated
mechanisms.
In our whole-genome array-CGH screening of 65 child-
hood ALL, we found 9p21 deletions in 18 cases, corre-
sponding to a frequency of 27.7%, comparable to the 29%
reported by Bungaro et al. (2009) in a pediatric ALL sam-
ple analyzed with a similar approach. In the present study,
23 breakpoint junctions of 9p21 deletions were cloned from
17 acute lymphoblastic leukemias of childhood, consisting
of 8 T- and 9 B-lineage samples, for a total of 46 break-
points (at least two breakpoints for each case; some cases
had diVerent breakpoints in each homologue). Our aim was
to examine which speciWc sequences, if any, are responsible
for the deletion and if genomic architecture acts as
susceptibility factor for the deletion itself.
The deletions we analyzed vary between 35 kb and
17 Mb in size: 33% of them are homozygous, and 44%
smaller than 1 Mb. Breakpoint junction cloning revealed
that half of the breakpoints (11/24 and 12/22 in T- and B-
ALL cases, respectively) were Xanked by sequences similar
to the heptamer-recombination signal sequences (heptamer-
RSSs), which are targeted by the RAG complex in V(D)J
recombination. This mechanism, identiWed in 9p21 dele-
tions since 1997 (Cayuela et al. 1997), is applicable to
about half of the childhood ALLs, at odds with a recent
Fig. 2 a Graphic representation 
of the 9p21.3 deletions in all 18 
cases. Grey lines represent the 
deleted region of every allele of 
each case. Overlap of two lines for 
the same case indicates a 
homozygous deletion. b Detailed 
map of the MTAP/CDKN2A/
CDKN2B region. The ten cases 
whit homozygous/heterozygous 
deletions, whose breakpoints (at 
least one) map between 
21,800,000 and 22,100,000 bp, 
are reportedHum Genet (2009) 126:511–520 517
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estimate (Kohno and Yokota 2006). In physiological V(D)J
recombination, several nucleotides are often added at DNA
ends before joining to increase the diversity of immuno-
globulin and T cell receptor gene products (Meier and
Lewis 1993). It must be noted that we found nucleotide
insertions, from 1 to 12 nucleotides, at the breakpoint
junctions of 9p21 deletions in the majority (20/23) of the
junctions, not just where RSSs-like heptamer sequences were
present, in accordance with the Wnding that 10–20% of
non-homologous junction in mammalian cells have nucleo-
tides inserted at the junction (Roth et al. 1989). In one case
(219-07), the inserted sequence was longer (427 bp) and
came from 4q32.3, underscoring the complexity of rear-
rangement events in cancer cells (Bignell et al. 2007).
Although many studies on cancer-related structural
variations report microhomology at the junctions in a large
proportion of the rearrangements (Bignell et al. 2007), we
found only a single case with an overlap of six nucleotides
(1460-07). In our cohort, the great majority of the junctions
have no homology between distal and proximal ends (22/23,
95%). The breakpoints fall only partially into previously iden-
tiWed cluster sites (Kohno and Yokota 1999) with two notable
exceptions. In one case (1329-07), the proximal breakpoint
overlaps the breakpoint of three previously analyzed lines,
Table 1 Sequences of all characterized breakpoints in childhood ALLs
Case ALL
a Breakpoint
b Position
c Sequence
d Repeats
f
1460-07 T 
Distal BP1  chr9:20881065-20881130 ttatcatcatgtctgttgtgatgatctatg 
||||||||||||||||||||||||||||||
attaat
||||||
gatctttgaagttacgattgtaattgtttt Tigger1 
Junction 1   ttatcatcatgtctgttgtgatgatctatg  ATTAAT  CTCTGAAAAGTAACTTTACTGTATTCTGAT 
Proximal BP1  chr9:22098125-22098190 TCTCTCCTACTTTGTTTTCTTTATAATAGA
||||||
ATTAAT
||||||||||||||||||||||||||||||
CTCTGAAAAGTAACTTTACTGTATTCTGAT
Distal BP2  chr9:21552789-21552848 AATAAGCTTTTATGTGGAAGTTAGCAGATA
||||||||||||||||||||||||||||||
ATTTCAGTTTAAGTGATTTGACTGATGACA
Junction 2   AATAAGCTTTTATGTGGAAGTTAGCAGATA  CG
e AGAAGAAAGCAGTCCTGCTACAGAAAATtt
Proximal BP2  chr9:22545710-22545769 ggccccaCATAGGTGGGCATCAAATGATAA
||||||||||||||||||||||||||||||
AGAAGAAAGCAGTCCTGCTACAGAAAATtt LTR16D/L1MD 
547-07 T 
Distal BP  chr9:21815532-21815591 gtcattttgataatggccattgtggcctgg 
||||||||||||||||||||||||||||||
cacagtggttcacgcctgtaatcctagcac L1MA7/AluJB 
Junction   gtcattttgataatggccattgtggcctgg  AGG tgtgtgtgtgtgtgtgtgtgtgtCTTAGTC
Proximal BP  chr9:21983793-21983852 TCCTACtgtgtgtgtgtgtgtgtgtgtgtg
||||||||||||||||||||||||||||||
tgtgtgtgtgtgtgtgtgtgtgtCTTAGTC (TG)n 
218-07 T 
Distal BP  chr9:21527711-21527770 aatactttacagacaagcaaatgctgagag 
||||||||||||||||||||||||||||||
attttgtcaccaccaggcctgccctaaaag L1PA2 
Junction   aatactttacagacaagcaaatgctgagag  GG CAACTTTTTAAAGTTATTTAGAATTTAAGG
Proximal BP  chr9:22518231-22518287 AGTTCTCCAAGGCAGTATGGTACTTCTCTA
||||||||||||||||||||||||||||||
CAACTTTTTAAAGTTATTTAGAATTTAAGG
1562-06 T 
Distal BP  chr9:21909987-21910046 gaacttgtctctaatcctaatgtaacagaa 
||||||||||||||||||||||||||||||
atgtatatgatattacattaggattagaga MGR75B 
Junction   gaacttgtctctaatcctaatgtaacagaa  ATTATTGGTGGTTTTCTAGGGTAAACAGGG
Proximal BP  chr9:22105710-22105769 ATTATCAGCTTGGATCACATGGACTTGGGG
||||||||||||||||||||||||||||||
ATTATTGGTGGTTTTCTAGGGTAAACAGGG
217-07 T 
Distal BP  chr9:21815531-21815590 tgtcattttgataatggccattgtggcctg 
||||||||||||||||||||||||||||||
gcacagtggttcacgcctgtaatcctagca L1MA7/AluJB 
Junction   tgtcattttgataatggccattgtggcctg  TTTAAGTAAG gtgtgtgtgtCTTAGTCATTCCCACCCAGG
Proximal BP  chr9:21983806-21983865 gtgtgtgtgtgtgtgtgtgtgtgtgtgtgt
||||||||||||||||||||||||||||||
gtgtgtgtgtCTTAGTCATTCCCACCCAGG (TG)n 
147-07 T 
Distal BP1  chr9:21328422-21328481 aacatgacgttttacatttaggaaaagaaa 
||||||||||||||||||||||||||||||
ggactggtttgccagaattaatttggcaaa L2 
Junction 1   aacatgacgttttacatttaggaaaagaaa  TCTTAGTCCCAA AACAGACAGTGTGCCATATTGGTGTTATGC
Proximal BP1  chr9:22440703-22440762 ATTTAGGAAGATCCCACACAACCAAGATAG
||||||||||||||||||||||||||||||
AACAGACAGTGTGCCATATTGGTGTTATGC
Distal BP2  chr9:21831409-21831468 gctaaccagagatcctgaatatgtccacat 
||||||||||||||||||||||||||||||
gacaacttcactgctagcataagcagcatt L1PB1 
Junction 2   gctaaccagagatcctgaatatgtccacat  TAAT atctgattttcttttttctgcttcttgctg
Proximal BP2  chr9:22310602-22310661 gaggcagataggagggtgggcactaattca
||||||||||||||||||||||||||||||
atctgattttcttttttctgcttcttgctg MLT1B 
1321-07 T 
Distal BP1  chr9:21435322-21435381 GAAGAGCCTGAAATTGCAGAGGAGTCTCTT 
||||||||||||||||||||||||||||||
CATGTATCCCTCAGGCCACACATTGTGata (TA)n 
Junction 1   GAAGAGCCTGAAATTGCAGAGGAGTCTCTT  GTGT CAAGGCTATGTGACTCAGGGAATAACCAAG
Proximal BP1  chr9:23928414-23928473 TAAATTCTTTATTGACTTTGGCTCAAGTGG
||||||||||||||||||||||||||||||
CAAGGCTATGTGACTCAGGGAATAACCAAG
Distal BP2  chr9:21788241-21788300 CTCTTTCACTGAGGGAGGTATAGGGTTCAG 
||||||||||||||||||||||||||||||
GGCTTAATCTTACACTTTGCTTATCCTATA
Junction 2   CTCTTTCACTGAGGGAGGTATAGGGTTCAG  TCAT tttttaCCATGAAATAAATTTTATCTGAAG
Proximal BP2  chr9:24962814-24962873 AACaaatttaattttaaatattgtaattta
||||||||||||||||||||||||||||||
tttttaCCATGAAATAAATTTTATCTGAAG AT-rich 
219-07 T 
Distal BP1  chr9:21055684-21055743 TTATATTCAAAGAGATGCTGGAACGAGGAA 
||||||||||||||||||||||||||||||
GAGGTTAAAGAGAGATTATTTGCCATCTTG
Junction 1   TTATATTCAAAGAGATGCTGGAACGAGGAA  CCC chr9:22709999-22710226(rev)  ATTCTTACTATATAACATTAGGTGCTTCCA
Proximal BP1  chr9: 22710197-22710256 AGACATCTGATTATAATCAGTACTCTATTT
||||||||||||||||||||||||||||||
ATTCTTACTATATAACATTAGGTGCTTCCA
Distal BP2  chr9:21738571-21738630 GTGAAGAATCTGAGCTTCCTAGATCTTatc 
||||||||||||||||||||||||||||||
tgatctaaatcctgcctctgtcagatctt MIRb 
Junction 2   GTGAAGAATCTGAGCTTCCTAGATCTTatc  chr4:163284405-163284832 gtattctgttaattacagGTAAAACAGCAA
Proximal BP2  chr9:23484206-23484265 caaacttctatttgtctaaggaattttaag
||||||||||||||||||||||||||||||
gtattctgttaattacagGTAAAACAGCAA MLT1J 
402-06 B 
Distal BP  chr9:19785967-19786027 tagggacatggatgaagctggaaaccatca 
||||||||||||||||||||||||||||||
ttctcagcaaactatcgtaaggacaaaaaac L1PA4 
Junction   tagggacatggatgaagctggaaaccatca  GGCG gtgtatcatacattttcatggataaaaaga
Proximal BP  chr9:22514478-22514537 tatttatacttctataattcatttagcgaa
||||||||||||||||||||||||||||||
gtgtatcatacattttcatggataaaaaga L3 518 Hum Genet (2009) 126:511–520
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BCS-LL3 (Kitagawa et al. 2002); this sequence has a V(D)J
recombination potential only 150-fold lower than the
canonical consensus recombination signal sequence (Kitagawa
et al. 2002). In three cases (547-07, 217-07 and 46-07), the
distal breakpoint falls in the same (GT)n repeat identiWed as
BCS-LL2 in previous reports (Kitagawa et al. 2002). This site
does not show unusual V(D)J recombination potential, but the
(GT)n tract could adopt a non-B DNA structure (Bacolla and
Wells 2004), which might enhance its potential for double-
strand break formation. The repeat is contained in the
D9S1748 STS and shows a considerable degree of
polymorphic variation. Typing of our samples for D9S1748
did not reveal any association between breakpoints within
BCS-LL2 and any speciWc D9S1748 allele (not shown).
Polymorphism at D9S1748 does not seem to be a predispos-
ing factor for chromosome 9p deletion in ALL.
Alterations in the regulation and pattern of DNA
methylation are essential for tumor progression. Our anal-
ysis of CDKN2A and CDKN2B promoters showed that
methylation took place in all cases without homozygous
deletion. Similar data have been reported for 9p21
deletions found in other tumors, supporting the concept
that, in accordance with the two-hit hypothesis (Knudson
1971), hypermethylation of promoter-associated CDKN2A
and  CDKN2B CpG islands is the primary mechanism
acting to inactivate the second allele in cases with a
heterozygous deletion (Knudson 2001). According to our
data, no relationship seems to exist between the size or
Table 1 continued
a ALL classiWcation (T-ALL or B-ALL)
b BP1 and BP2 always refer to the two alleles in heterozygous deletions except for 888-06 and 314-07, where BP2 is a copy number variation
c Breakpoint position (hg18 assembly); the position of distal and proximal reference sequences is indicated
d Sequence of breakpoint junctions aligned to the reference sequences; repeated sequences are shown in lowercase letters
e Additional bases not present in the reference sequence are shown in bold; inversions (in 219-07 Bp1 and 1623-06) and long insertions (in
219-07 Bp2) are also indicated. RSS motifs are highlighted in grey (heptamer) and yellow (nonamer); bases matching the motif consensus sequences
are red
f Repeated sequences located within 60 bp from the breakpoints
888-06 B 
Distal BP1  chr9:21931325-21931384 GGCTAATATCAAGATTAGCACTAGCTGTCT 
||||||||||||||||||||||||||||||
GTAGATACCATTTAGAAAAGTTTTCTCTAC
Junction 1   GGCTAATATCAAGATTAGCACTAGCTGTCT  AGT GAACAATAAGCAAATAAATTCAATTTTCTC
Proximal BP1  chr9:22051314-22051373 gacattttttcctttactagccaaaaGGGA
||||||||||||||||||||||||||||||
GAACAATAAGCAAATAAATTCAATTTTCTC simple repeat 
Distal BP2  chr9:22486498-22486557 aaaaatattcctgcagctagctcagtgtct 
||||||||||||||||||||||||||||||
acccaaatggccacctggttttgtgcttca L1PA7 
Junction 2   aaaaatattcctgcagctagctcagtgtct  T cttggcaatgtgggcacttttttggttcca
Proximal BP2  chr9:22494315-22494374 tccagctttgttcttttggcttaggattgg
||||||||||||||||||||||||||||||
cttggcaatgtgggcacttttttggttcca L1PA4 
46-07 B 
Distal BP  chr9:21823933-21823992 ACTCTCTTGAACTCATTTTTCCTGCCAGCA 
||||||||||||||||||||||||||||||
CACATCATTTTGTCTCCTTTACTTTTCCAT
Junction   ACTCTCTTGAACTCATTTTTCCTGCCAGCA  TGAGAA gtgtgtgtgtgtgtgtgtgtCTTAGTCATT
Proximal BP  chr9:21983796-21983855 TACtgtgtgtgtgtgtgtgtgtgtgtgtgt
||||||||||||||||||||||||||||||
gtgtgtgtgtgtgtgtgtgtCTTAGTCATT (TG)n 
314-07 B 
Distal BP1  chr9:20598253-20598312 ATGACAGTCTTTTTATTTGTAGTTGATTTT 
||||||||||||||||||||||||||||||
TAAAGTCAGATGTAGGCTCTAGAAAAATTT
Junction 1   ATGACAGTCTTTTTATTTGTAGTTGATTTT  GGGCTCCCCGC aatgtcttcttttgaggagtgtctgttcat
Proximal BP1  chr9:22320169-22320228 gagcattttttcatgtctgttggccgcata
||||||||||||||||||||||||||||||
aatgtcttcttttgaggagtgtctgttcat L1PA7 
Distal BP2  chr9:22486498-22486557 aaaaatattcctgcagctagctcagtgtct 
||||||||||||||||||||||||||||||
acccaaatggccacctggttttgtgcttca L1PA7 
Junction 2   aaaaatattcctgcagctagctcagtgtct  T cttggcaatgtgggcacttttttggttcca
Proximal BP2  chr9:22494315-22494374 tccagctttgttcttttggcttaggattgg
||||||||||||||||||||||||||||||
cttggcaatgtgggcacttttttggttcca L1PA4 
1327-07 B 
Distal BP  chr9:21915849-21915908 tggccttcttggtgcttatgtcttcatggg 
||||||||||||||||||||||||||||||
caattatcctccaaggtgatggggttaaat MER50-int
Junction   tggccttcttggtgcttatgtcttcatggg  catccttaaccacaatactctaTGAATCCT
Proximal BP  chr9:22101282-22101341 ctgaattcagcagtctgttaccatagtttt
||||||||||||||||||||||||||||||
catccttaaccacaatactctaTGAATCCT MIR 
1329-07 B 
Distal BP  chr9:21965776-21965835 AAAAGTGCTCAGTGTTCTAGAAGCAGAGTT 
||||||||||||||||||||||||||||||
GCACAGTGATCCAAAGACCAGCTTCAAATA
Junction   AAAAGTGCTCAGTGTTCTAGAAGCAGAGTT  CTCGA GAATCCCGTCTCATTCTCAATTAACCTCTA
Proximal BP  chr9:21998277-21998336 ACATAAAAGGAACTAAGTACTGTGGTTGAG
||||||||||||||||||||||||||||||
GAATCCCGTCTCATTCTCAATTAACCTCTA
886-07 B 
Distal BP  chr9:21277034-21277093 TGATTTTCCACCTACACAATCACCAAGTGT 
||||||||||||||||||||||||||||||
AAGTTCACAAAATATAATGCAGCAAAATTG
Junction   TGATTTTCCACCTACACAATCACCAAGTGT  CCCTATC AACACTAGAATTGGAATGGCCTTGAAGGTG
Proximal BP  chr9:22914787-22914846 AACATTTATAAAATATGCCTTTTGAGAGAA
||||||||||||||||||||||||||||||
AACACTAGAATTGGAATGGCCTTGAAGGTG
1623-06 B 
Distal BP  chr9:21106872-21106931 aggcatttaatgctacgaactttcctctta 
||||||||||||||||||||||||||||||
gcaccacttttgctgtatcccggaagtttt L1PB7 
Junction   aggcatttaatgctacgaactttcctctta  chr9:21106887-21107155(rev) CCCCCCT ttagttagttttgtcatcagtcaaagggga
Proximal BP  chr9:22062503-22062562 cctgcacatgtagcttaagctatctaagcc
||||||||||||||||||||||||||||||
ttagttagttttgtcatcagtcaaagggga MIRb 
1063-07 B 
Distal BP  chr9:20578216-20578275 cagtaccatgctgttttggtgactgtagcc 
||||||||||||||||||||||||||||||
ttgtagtatagtttgaagtcaggtagtgtg L1PA3 
Junction   cagtaccatgctgttttggtgactgtagcc  CCTTAAGG ccatttaggaaactctgCTCTAAGGAATTA
Proximal BP  chr9:22195162-22195221 agattccctgatttctagggattatggacc
||||||||||||||||||||||||||||||
ccatttaggaaactctgCTCTAAGGAATTA Charlie4AHum Genet (2009) 126:511–520 519
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structure of the heterozygous deletion and the ability of
the remaining allele to undergo promoter methylation.
In conclusion, our data show that diVerent molecular
mechanisms underlie the 9p21 deletion in childhood ALL.
In half of the cases, the deletion is mediated by ectopic
V(D)J recombination at RSSs-like sequences. Microho-
mology-mediated deletion, reported as frequent in cancer
structural variations, was found only in one case. In the
remaining cases, repeated sequences, including (GT)n, with
left-handed Z-DNA conformation potential, were detected
at the breakpoint junctions. Insertions are common at
breakpoint junctions. We identiWed only two cases sharing
identical deletions. Four of our 46 breakpoints coincide
with previously reported breakpoints, thus conWrming the
presence of recurrent deletion hotspots. In general, most of
the breakpoints are non-recurrent and generate deletions of
variable size. Our data partially answer the unsolved ques-
tions stressed by Kohno and Yokota (2006) showing that
the chromatin architecture that makes DNA susceptible to
DSBs is similar to the one detected in constitutional geno-
mic disorders, with repeated sequences regions of DNA
with non-B conformation potential playing a crucial role in
predisposing to genome instability (Bacolla and Wells
2004; Wells 2007). However, we cannot exclude that dele-
tion occurrence may also be inXuenced by other factors,
such as interaction between cis- (Jones et al. 2009; Olcaydu
et al.  2009; Kilpivaara et al. 2009) and trans-acting
elements, as recently suggested in mouse meiotic recombi-
nation (Parvanov et al. 2009). Further studies are necessary
to Wnd out which haplotypes, if any, predispose to these
somatic rearrangements.
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